US2003083472A1PendingUtilityA1

Cell surface molecule mediating cell adhesion and signal transmission

56
Assignee: JAPAN TOBACCO INC A JAPANESE CPriority: Feb 27, 1997Filed: Nov 21, 2002Published: May 1, 2003
Est. expiryFeb 27, 2017(expired)· nominal 20-yr term from priority
Inventors:Takuya TamataniKatsunari Tezuka
A61P 37/08A61P 37/06A61P 37/02A61P 37/00C07K 14/70521C07K 14/4713A61K 38/00C07K 14/705C07K 2319/00A61P 29/00A01K 2217/075A01K 2217/05
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A pharmaceutical composition comprising a drug that regulates the function of a JTT-1 antigen.  
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the drug is a low molecular weight compound.  
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the drug is an antisense substance.  
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the drug is a polypeptide.  
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition activates or stimulates the function of the JTT-1 antigen.  
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein the drug is a low molecular weight compound.  
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the drug is a low molecular weight compound.  
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is effective at treating or preventing an autoimmune disease, an allergic disease, or an inflammatory disease.  
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the drug is a low molecular weight compound.  
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the JTT-1 antigen is a human JTT-1 antigen.  
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein the JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2.  
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the JTT-1 antigen consists of the amino acid sequence of SEQ ID NO:2.  
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the drug is a low molecular weight compound.  
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the pharmaceutical composition inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         16 . The pharmaceutical composition of  claim 1 , wherein the JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added, and wherein 
 (a) the JTT-1 antigen comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region,    (b) the JTT-1 antigen comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and    (c) an antibody reactive with the JTT-1 antigen induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3.    
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the drug is a low molecular weight compound.  
     
     
         18 . A method of treating a disease selected from the group consisting of an autoimmune disease, an allergic disease, or an inflammatory disease in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of  claim 1 .  
     
     
         19 . The method of  claim 18 , wherein the disease is an autoimmune disease.  
     
     
         20 . The method of  claim 18 , wherein the disease is an allergic disease.  
     
     
         21 . The method of  claim 18 , wherein the disease is an inflammatory disease.  
     
     
         22 . The method of  claim 18 , wherein the disease is rheumatoid arthritis, multiple sclerosis, autoimmune thyroiditis, allergic contact dermatitis, chronic inflammatory dermatosis, systemic lupus erythematosus, insulin dependent diabetes mellitus, or psoriasis.  
     
     
         23 . The method of  claim 18 , wherein the drug is a low molecular weight compound.  
     
     
         24 . The method of  claim 18 , wherein the drug is an antisense substance.  
     
     
         25 . The method of  claim 18 , wherein the drug is a polypeptide.  
     
     
         26 . The method of  claim 18 , wherein the drug is an antibody.  
     
     
         27 . The method of  claim 18 , wherein the pharmaceutical composition activates or stimulates the function of the JTT-1 antigen.  
     
     
         28 . The method of  claim 27 , wherein the drug is a low molecular weight compound.  
     
     
         29 . The method of  claim 18 , wherein the pharmaceutical composition inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         30 . The method of  claim 29 , wherein the drug is a low molecular weight compound.  
     
     
         31 . The method of  claim 18 , wherein the JTT-1 antigen is a human JTT-1 antigen.  
     
     
         32 . The method of  claim 18 , wherein the JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2.  
     
     
         33 . The method of  claim 32 , wherein the JTT-1 antigen consists of the amino acid sequence of SEQ ID NO:2.  
     
     
         34 . The method of  claim 33 , wherein the drug is a low molecular weight compound.  
     
     
         35 . The method of  claim 34 , wherein the pharmaceutical composition inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         36 . The method of  claim 18 , wherein the JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added, and wherein 
 (a) the JTT-1 antigen comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region,    (b) the JTT-1 antigen comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and    (c) an antibody reactive with the JTT-1 antigen induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3.    
     
     
         37 . The method of  claim 36 , wherein the drug is a low molecular weight compound.  
     
     
         38 . A method of identifying a substance that regulates JTT-1 antigen function, the method comprising: 
 providing a transgenic mouse transgenic for human JTT-1 antigen;    administering a test substance to the mouse; and    determining whether the test substance regulates the function of human JTT-1 antigen.    
     
     
         39 . The method of  claim 38 , wherein the test substance is a low molecular weight compound.  
     
     
         40 . The method of  claim 38 , wherein the test substance is an antisense substance.  
     
     
         41 . The method of  claim 38 , wherein the test substance is a polypeptide.  
     
     
         42 . The method of  claim 38 , wherein the test substance is an antibody.  
     
     
         43 . The method of  claim 38 , wherein the determining step determines whether the test substance activates or stimulates the function of the JTT-1 antigen.  
     
     
         44 . The method of  claim 43 , wherein the test substance is a low molecular weight compound.  
     
     
         45 . The method of  claim 38 , wherein the determining step determines whether the test substance inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         46 . The method of  claim 45 , wherein the test substance is a low molecular weight compound.  
     
     
         47 . The method of  claim 38 , wherein the human JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2.  
     
     
         48 . The method of  claim 47 , wherein the human JTT-1 antigen consists of the amino acid sequence of SEQ ID NO:2.  
     
     
         49 . The method of  claim 48 , wherein the test substance is a low molecular weight compound.  
     
     
         50 . The method of  claim 49 , wherein the determining step determines whether the test substance inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         51 . The method of  claim 38 , wherein the human JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added, and wherein 
 (a) the human JTT-1 antigen comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region,    (b) the human JTT-1 antigen comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and    (c) an antibody reactive with the human JTT-1 antigen induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3.    
     
     
         52 . The method of  claim 51 , wherein the test substance is a low molecular weight compound.  
     
     
         53 . A method of identifying a substance that regulates JTT-1 antigen function, the method comprising: 
 providing a purified polypeptide comprising the extracellular domain of a JTT-1 antigen;    contacting the polypeptide with a test substance; and    determining whether the test substance interacts with the polypeptide, wherein such interaction indicates that the test substance is a potential regulator of JTT-1 antigen.    
     
     
         54 . The method of  claim 53 , wherein the polypeptide is a fusion protein.  
     
     
         55 . The method of  claim 54 , wherein the fusion protein comprises a portion of a constant region of an immunoglobulin heavy chain.  
     
     
         56 . The method of  claim 53 , wherein the extracellular region is amino acid residues 1-140 of SEQ ID NO:2.  
     
     
         57 . The method of  claim 53 , wherein the test substance is a low molecular weight compound.  
     
     
         58 . The method of  claim 53 , wherein the test substance is a polypeptide.  
     
     
         59 . The method of  claim 53 , wherein the test substance is an antibody.  
     
     
         60 . The method of  claim 53 , wherein the test substance activates or stimulates the function of the JTT-1 antigen.  
     
     
         61 . The method of  claim 60 , wherein the test substance is a low molecular weight compound.  
     
     
         62 . The method of  claim 53 , wherein the test substance inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         63 . The method of  claim 62 , wherein the test substance is a low molecular weight compound.  
     
     
         64 . The method of  claim 53 , wherein the human JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2.  
     
     
         65 . The method of  claim 64 , wherein the human JTT-1 antigen consists of the amino acid sequence of SEQ ID NO:2.  
     
     
         66 . The method of  claim 65 , wherein the test substance is a low molecular weight compound.  
     
     
         67 . The method of  claim 66 , wherein the test substance inhibits or suppresses the function of the JTT-1 antigen.  
     
     
         68 . The method of  claim 53 , wherein the human JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added, and wherein 
 (a) the human JTT-1 antigen comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region,    (b) the human JTT-1 antigen comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and    (c) an antibody reactive with the human JTT-1 antigen induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3.    
     
     
         69 . The method of  claim 68 , wherein the test substance is a low molecular weight compound.

Join the waitlist — get patent alerts

Track US2003083472A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.